Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.
Resistance Training, Nutritional Interventions Prevent Muscle Loss During, After Radiotherapy for Head and Neck CancerAugust 01, 2017
Intervention with resistance training and nutritional supplements during and after radiation therapy is not only feasible, but also shown to prevent loss of muscle mass and improve quality of life in patients with head and neck cancer (HNC).
Findings at 6 and 12 months after treatment for advanced head and neck cancer indicate a higher risk of recurrences for those reporting cachexia after their treatment.
[Clinical Medicine Insights: Oncology] A case study of a 49-year-old premenopausal woman with metastatic invasive ductal breast carcinoma in the vertebral and iliac bones, which progressed with new metastases to her hips, thigh bones, and vertebrae.
Loss of appetite and not eating are difficult aspects of cancer for patients' loved ones to understand. Continued and diligent nurse education can help both patients and families cope with this disturbing effect.
A new drug is proven to offer significantly better outcomes for patients with non-small cell lung cancer who experience this debilitating side effect.
A new drug, anamorelin, has been found to improve appetite and body mass in patients with advanced lung cancer who are experiencing cancer anorexia and cachexia.
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|